• S2 Episode 2: Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening

  • Feb 16 2023
  • Length: 25 mins
  • Podcast

S2 Episode 2: Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening

  • Summary

  • Drs Jacob Sands and Julia Rotow discuss genomic testing, treatment options, and clinical trials for young adults who do not qualify for lung cancer screening.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984258). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Lung Cancer https://www.medscape.com/resource/lungcancer

    Lung Cancer in Patients Under the Age of 40 Years https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687453/

    Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States https://jamanetwork.com/journals/jamaoncology/article-abstract/2773380

    What Are the Risks and Benefits of Lung Cancer Screening? https://www.medscape.com/viewarticle/969532

    Biomarker Tissue Journey Among Patients With Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network https://pubmed.ncbi.nlm.nih.gov/35313244/

    Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States https://pubmed.ncbi.nlm.nih.gov/35737912/

    Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer https://jamanetwork.com/journals/jamaoncology/fullarticle/2475482

    Biology of Young Lung Cancer Study: The YOUNG LUNG Study https://clinicaltrials.gov/ct2/show/NCT05265429

    Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) https://www.clinical-lung-cancer.com/article/S1525-7304(22)00265-0/fulltext

    Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations https://linkinghub.elsevier.com/retrieve/pii/S1525-1578(22)00080-0

    Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482929/

    Immune Checkpoint Inhibitors for Patients With Advanced Lung Cancer and Oncogenic Driver Alterations: Results From the IMMUNOTARGET Registry https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389252/

    Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/

    Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(22)01068-6

    Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Induced Hepatic Failure in Lung Cancer Patients: A Study of Signal Mining and Analysis of the FDA Adverse Event Reporting System Database https://pubmed.ncbi.nlm.nih.gov/33768534/

    A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) https://www.clinicaltrials.gov/ct2/show/NCT03157128

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about S2 Episode 2: Young Adults and Lung Cancer: Testing and Treatment Options for a Population That Does Not Qualify for Screening

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.